|Project Title||Principal Investigator||Institution|
|A non-human primate autism model based on maternal infection||Patterson, Paul||California Institute of Technology|
|Role of Wnt signaling through Dishevelled, Dact and p120catenin in forebrain development, synaptic physiology, and mouse behavior: Exploration of a pathway with many components linked to autism spectrum disorders||Reichardt, Louis||University of California, San Francisco|
|Perturbed activity dependent plasticity mechanisms in autism||Sabatini, Bernardo||Harvard Medical School|
|Models and mechanisms - 2||Sahin, Mustafa||Boston Children's Hospital|
|Oxidative stress: Rat study||Sajdel-Sulkowska, Ellen||Brigham and Women's Hospital|
|Connectopathic analysis of autism||Sanes, Joshua||Harvard University|
|Genetic analyses of ARX homeobox gene function in neurodevelopmental disorders||Sengupta, Piali||Brandeis University|
|Mice lacking Shank postsynaptic scaffolds as an animal model of autism||Sheng, Morgan||Massachusetts Institute of Technology|
|Using zebrafish and chemical screening to define function of autism genes||Sive, Hazel||Whitehead Institute for Biomedical Research|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Aberrant synaptic function due to TSC mutation in autism||Sulzer, David||Columbia University Medical Center|
|Models and mechanisms - 1||Sur, Mriganka||Massachusetts Institute of Technology|
|Neural and cognitive mechanisms of autism||Sur, Mriganka||Massachusetts Institute of Technology|
|Cognitive mechanisms of serially organized behavior||Terrace, Herbert||Columbia University|
|Regulation of synaptogenesis by cyclin dependent kinase 5||Tsai, Li-Huei||Massachusetts Institute of Technology|
|Probing a monogenic form of autism from molecules to behavior||Tsien, Richard||Stanford University|
|Regulation of gene expression in the brain||Young, Walter||National Institutes of Health|
|IACC Strategic Plan Objectives||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built.Â The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.